Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant

Vaccines (Basel). 2022 Oct 16;10(10):1728. doi: 10.3390/vaccines10101728.

Abstract

The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant. Due to the possibility of reinfection, booster vaccinations are necessary. Further epidemiological and clinical studies are necessary to develop new prevention strategies.

Keywords: COVID-19; NCP; RBD; S2; SARS CoV-2 antibody; SARS-CoV-2; delta variant; omicron variant; vaccination.